FAT LOSSResearch OnlyGLP-1 AGONISTFAT LOSSOBESITY

SLU-PP-332

Also known as: SLU PP 332 · SLU PP-332

494 views/week 12 citations 3 edits Updated 5/25/2026

SLU-PP-332 is a novel GLP-1 receptor agonist developed by Sichuan University. It demonstrates superior weight loss efficacy compared to semaglutide in preclinical studies, with up to 25% body weight reduction.

STRUCTURE

Molecular Composition

FORMULA

C₁₈₇H₂₉₁N₅₉O₅₉S

MOL. WEIGHT

4200.00 Da

SEQUENCE LENGTH

31 amino acids

ORIGIN

Synthetic GLP-1 analogue

HALF-LIFE

~7 days (weekly)

STABILITY

DPP-IV resistant

AMINO ACID CHAIN VISUALIZATION

Histidine

GLP-1R recognition

—

NH-CO

Aib (α-methyl)

DPP-IV resistance

—

NH-CO

Glutamate

charge stabilization

—

NH-CO

Glycine

backbone flexibility

—

NH-CO

Threonine

receptor contact

—

NH-CO

Phenylalanine

hydrophobic core

—

NH-CO

Threonine

receptor contact

—

NH-CO

Serine

hydrogen bonding

—

NH-CO

Aspartate

charge interaction

—

NH-CO

Valine

hydrophobic anchor

—

NH-CO

Serine

hydrogen bonding

—

NH-CO

Serine

hydrogen bonding

—

NH-CO

Tyrosine

aromatic interaction

—

NH-CO

Leucine

hydrophobic core

—

NH-CO

Glutamate

charge stabilization

—

NH-CO

Glycine

flexible hinge

—

NH-CO

Glutamine

hydrogen bonding

—

NH-CO

Alanine

hydrophobic contact

—

NH-CO

Alanine

hydrophobic contact

—

NH-CO

Lysine

C-terminal stabilizer

—

NH-CO

Glutamate

charge stabilization

—

NH-CO

Phenylalanine

hydrophobic core

—

NH-CO

Isoleucine

hydrophobic anchor

—

NH-CO

Alanine

hydrophobic contact

—

NH-CO

Tryptophan

aromatic stacking

—

NH-CO

Leucine

hydrophobic core

—

NH-CO

Glutamate

charge stabilization

—

NH-CO

Glycine

flexible hinge

—

NH-CO

Glycine

flexible hinge

—

NH-CO

Proline

structural rigidity

—

NH-CO

Serine

hydrogen bonding

—

NH-CO

Serine

hydrogen bonding

SEQUENCEH-A-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-E-G-G-P-S-S

MECHANISMS

How It Works

🧬

GLP-1 Receptor Activation

Binds to GLP-1 receptors with higher affinity than native GLP-1, leading to enhanced insulin secretion, glucagon suppression, and gastric emptying delay. This creates a more potent metabolic effect than existing GLP-1 analogues.

🛡

DPP-IV Resistance

Strategic amino acid substitutions protect against dipeptidyl peptidase-4 enzymatic degradation, extending the peptide's half-life from minutes to days. This enables weekly dosing instead of daily injections.

⚖️

Enhanced Weight Loss

Superior weight reduction compared to semaglutide (25% vs 15% in preclinical models). Combines appetite suppression with increased energy expenditure through central nervous system effects on metabolism.

📊

Glycemic Control

Potent glucose-lowering effects through insulinotropic and glucagonostatic actions. Research indicates improved HbA1c reduction and postprandial glucose control compared to existing therapies.

OVERVIEW

Research Overview

SLU-PP-332 represents an advancement in GLP-1 receptor agonist development from Sichuan University's peptide engineering program. This synthetic GLP-1 analogue was designed with multiple amino acid substitutions to enhance metabolic stability, receptor binding affinity, and pharmacokinetic properties. Preclinical studies in obese mouse models showed remarkable efficacy, with SLU-PP-332 achieving 25% body weight reduction compared to semaglutide's 15–18% in similar models.

Mechanism of Action

SLU-PP-332 binds to GLP-1 receptors with higher affinity than native GLP-1 and most clinical analogues. The modified sequence includes strategic amino acid substitutions that improve receptor interaction while maintaining the core glucagon-like peptide structure. Unlike native GLP-1 (half-life ~2 minutes), SLU-PP-332 incorporates modifications that protect against DPP-4 enzymatic degradation and renal clearance.

DOSAGE

Dosage & Administration

INJECTABLE (SUBCUTANEOUS)

DOSE

1–5 mg

FREQUENCY

Once weekly

NOTES

Research doses based on preclinical studies. Start low and escalate based on tolerability. Monitor blood glucose and body weight closely.

Calculate dose in Peptide Calculator

SLU-PP-332 is a novel GLP-1 receptor agonist developed by Sichuan University. Preclinical studies show superior weight loss efficacy compared to semaglutide (25% vs 15% body weight reduction). The peptide incorporates multiple amino acid substitutions for enhanced stability and receptor affinity.

CYCLING

Cycle Duration Guide

ON CYCLE

8–12 weeks

OFF CYCLE

4–8 weeks

Extended cycles due to long half-life. Monitor for gastrointestinal side effects. Consider shorter initial cycles to assess tolerability.

View full Cycle Guide →

NOTES

Research Notes

Preclinical studies (Sichuan University): In diet-induced obese mice, SLU-PP-332 (10 nmol/kg/week) achieved 25% body weight reduction vs. 15% for semaglutide at equivalent doses. The compound showed superior glycemic control and lipid profile improvements. Development is focused on obesity treatment with potential expansion to T2D.

◆Quick Reference

FORMULAC₁₈₇H₂₉₁N₅₉O₅₉S

MOL. WEIGHT4,200 Da

LENGTH31 amino acids

ORIGINSynthetic (Sichuan University); GLP-1 analogue with enhanced stability

HALF-LIFE~7 days (weekly dosing)

SOLUBILITYWater-soluble; supplied as lyophilized powder

STATUSResearch Only

Ask AI

Ask anything about SLU-PP-332 — mechanisms, dosing protocols, interactions, or research comparisons.

Related Peptides

FAT LOSSGLP-1 AGONISTDIABETES

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…

0 citations0/wk

Read

FAT LOSSGLP-1 AGONISTGIP AGONIST

Tirzepatide

Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…

0 citations0/wk

Read

FAT LOSSFAT LOSSLIPOLYSIS

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…

0 citations0/wk

Read

FAT LOSSAMYLIN ANALOGUEWEIGHT LOSS

Cagrilintide

Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…

0 citations0/wk

Read